Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates
Authors:
- R. Dilshan MalewanaRMR. Dilshan Malewana
- Victoria StallsVSVictoria Stalls
- Aaron MayAMAaron May
- Xiaozhi LuXLXiaozhi Lu
- David R. MartinezDMDavid R. Martinez
- Alexandra SchäferASAlexandra Schäfer
- Dapeng LiDLDapeng Li
- Laura L. SutherlandLSLaura L. Sutherland
- Robert ParksRPRobert Parks
- Whitney Edwards BeckWBWhitney Edwards Beck
- 11 June 2025
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (802) , eadn5651
Abstract
Immunization with messenger RNA (mRNA) or viral vectors encoding spike protein with diproline substitutions (S-2P) were shown to provide protective immunity, curbing the COVID-19 pandemic. However, in light of the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that can cause COVID-19, it is essential that we understand how immunization with spike protein elicits neutralizing antibodies (nAbs). Here, we compared immunization of macaques with mRNA vaccines expressing ancestral spike protein with or without diproline substitutions, showing that the diproline substitutions were not required for protection against SARS-CoV-2 challenge or induction of broadly neutralizing B cell lineages. One group of nAbs elicited by the ancestral spike protein lacking diproline substitutions targeted the outer face of the receptor binding domain (RBD), neutralized all tested SARS-CoV-2 VOC pseudotyped viruses including Omicron XBB.1.5 in vitro, but lacked cross-sarbecovirus neutralization. Structural analysis showed that the macaque nAbs that could broadly neutralize VOCs bound to the same epitope as a human nAb, DH1193. In contrast, vaccine-induced antibodies that targeted the RBD inner face neutralized multiple sarbecoviruses, protected mice from bat CoV RsSHC014 challenge, but lacked Omicron variant neutralization. Thus, ancestral SARS-CoV-2 spike mRNA vaccines lacking proline substitutions can induce B cell lineages binding to distinct RBD sites that either broadly neutralize animal and human sarbecoviruses or neutralize recent Omicron VOCs. Thus, the use of a nonstabilized spike protein design in some COVID-19 vaccines does not preclude the elicitation of broad sarbecovirus and broad VOC nAbs.Keywords
This publication has 68 references indexed in Scilit:
- Production and Evaluation of Nucleoside-Modified mRNA Vaccines for Infectious Diseases2024
- Tackling COVID-19 with neutralizing monoclonal antibodiesCell, 2021
- COVID-19-neutralizing antibodies predict disease severity and survivalCell, 2021
- A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory MiceCell, 2020
- Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution SerologyCell, 2020
- Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 VirusCell, 2020
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike GlycoproteinCell, 2020
- UCSF ChimeraX: Meeting modern challenges in visualization and analysisProtein Science, 2017
- HPLC Purification of In Vitro Transcribed Long RNA2012
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004